SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000947871-23-000412
Filing Date
2023-03-31
Accepted
2023-03-31 16:48:25
Documents
2
Group Members
ORBIMED ADVISORS III LTDORBIMED ASIA GP III, L.P.ORBIMED CAPITAL LLCORBIMED GENESIS GP LLCORBIMED NEW HORIZONS GP LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss1931459_sc13d.htm SC 13D 181016
2 JOINT FILING AGREEMENT ss1931459_ex9901.htm EX-99.1 9686
  Complete submission text file 0000947871-23-000412.txt   192428
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address BUILDING 3, 418 GUILIN ROAD XUHUI DISTRICT SHANGHAI F4 200030
Business Address BUILDING 3, 418 GUILIN ROAD XUHUI DISTRICT SHANGHAI F4 200030 00862164031522
Gracell Biotechnologies Inc. (Subject) CIK: 0001826492 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91967 | Film No.: 23788715
SIC: 2834 Pharmaceutical Preparations